Definium Therapeutics (DFTX) Q2 FY26 earnings call

Definium Therapeutics reported strong Q2 FY26 results, highlighted by positive Phase III Emerge data for DT120 ODT in MDD, showing a significant treatment effect. The company is rapidly advancing its pipeline with upcoming GAD data readouts and preparing for potential commercialization, supported by a strengthened balance sheet. The call did not include a Q&A session due to the imminent release of Voyage study results.